Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283150 · ClinicalTrials.gov registry record · Phase 4
Deep Brain Stimulation (DBS) Sedation
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT03283150 is a Phase 4 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 20 participants.
The verdict
NCT03283150, a Phase 4 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Deep brain stimulation (DBS) of different brain nuclei is a treatment for multiple brain disorders. The subthalamic nucleus (STN) and globus pallidus have been used to treat advanced Parkinson's disease for a long time. The ventral intermediate nucleus of the thalamus is an effective target for treating essential tremor patients. STN and the internal segment of the globus pallidus are useful targets for treating dystonia. To achieve this optimal electrode localization, many centers perform electrophysiological mapping of the target nuclei using microelectrode recording (MER). This way they can achieve precise localization of the electrode. During the mapping procedure, microelectrodes are passed through the target nuclei, and the electrical neuronal activity is observed and recorded. The surgical team can identify the precise location of the target nuclei and its borders according to the typical activity of its neurons. This study will compare the activity of neurons in several DBS targets before, during and after sedation with propofol, remifentanil and dexmedetomidine. The goal is to understand the effects of anesthetics on the neuronal activity in these targets, allowing us to choose the most appropriate sedation protocol to use during implantation of DBS electrodes in deep brain structures (bearing in mind that each structure may have a different optimal protocol).
Interventions
- DRUG Dexmedetomidine
- DRUG Propofol
- DRUG Remifentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283150
The ClinicalTrials.gov registry entry for NCT03283150 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexmedetomidine is the first listed.
NCT03283150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283150 about?
NCT03283150 is a clinical study titled "Deep Brain Stimulation (DBS) Sedation". Deep brain stimulation (DBS) of different brain nuclei is a treatment for multiple brain disorders. The subthalamic nucleus (STN) and globus pallidus have been used to treat advanced Parkinson's disease for a long time. The ventral intermediate nucleus of the thalamus is an effective target for trea...
What is the current status of trial NCT03283150?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2017-12-01. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT03283150?
The interventions under investigation include: Dexmedetomidine (DRUG), Propofol (DRUG), Remifentanil (DRUG).
Who is sponsoring clinical trial NCT03283150?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.